Mignon L Loh

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9143829/publications.pdf

Version: 2024-02-01

389	27,767	4388	6836
papers	citations	86 h-index	155 g-index

398	398	398	22439
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature, 2012, 481, 157-163.	27.8	1,430
2	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2014, 371, 1005-1015.	27.0	1,161
3	Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nature Genetics, 1999, 23, 166-175.	21.4	1,036
4	Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell, 2002, 1, 75-87.	16.8	1,024
5	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228.	1.4	814
6	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nature Genetics, 2017, 49, 1211-1218.	21.4	693
7	An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science, 2014, 346, 1373-1377.	12.6	665
8	Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia. Cancer Cell, 2012, 22, 153-166.	16.8	621
9	The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 242-252.	21.4	588
10	JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9414-9418.	7.1	516
11	Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia. Cancer Research, 2004, 64, 8816-8820.	0.9	472
12	Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood, 2004, 103, 2325-2331.	1.4	415
13	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood, 2007, 109, 926-935.	1.4	413
14	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nature Genetics, 2019, 51, 296-307.	21.4	384
15	Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nature Genetics, 2010, 42, 794-800.	21.4	308
16	Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Childrenâ€™s Oncology Group Study AALL0232. Journal of Clinical Oncology, 2016, 34, 2380-2388.	1.6	301
17	Stat5 Is Essential for the Myelo- and Lymphoproliferative Disease Induced by TEL/JAK2. Molecular Cell, 2000, 6, 693-704.	9.7	289
18	Prognostic significance of minimal residual disease in high risk B-ALL: a report from Childrenâ€™s Oncology Group study AALL0232. Blood, 2015, 126, 964-971.	1.4	287

#	Article	IF	Citations
19	Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nature Communications, 2015, 6, 6604.	12.8	281
20	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nature Genetics, 2013, 45, 1494-1498.	21.4	264
21	Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood, 2012, 120, 3510-3518.	1.4	263
22	Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood, 2009, 114, 1859-1863.	1.4	260
23	Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood, 2011, 118, 3080-3087.	1.4	255
24	Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nature Genetics, 2011, 43, 237-241.	21.4	239
25	Targetable kinase gene fusions in high-risk B-ALL: a study from the Childrenâ€™s Oncology Group. Blood, 2017, 129, 3352-3361.	1.4	236
26	The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature, 2018, 562, 373-379.	27.8	236
27	Association of an Inherited Genetic Variant With Vincristine-Related Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2015, 313, 815.	7.4	234
28	The genomic landscape of juvenile myelomonocytic leukemia. Nature Genetics, 2015, 47, 1326-1333.	21.4	233
29	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nature Genetics, 2016, 48, 1481-1489.	21.4	231
30	Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic Correlates. Cancer Cell, 2008, 14, 335-343.	16.8	219
31	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nature Communications, 2016, 7, 13331.	12.8	218
32	Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study. Blood, 2012, 119, 3512-3522.	1.4	210
33	Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment. Nature, 2016, 539, 304-308.	27.8	210
34	Novel Susceptibility Variants at 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. Journal of the National Cancer Institute, 2013, 105, 733-742.	6.3	208
35	High-Throughput Sequencing Detects Minimal Residual Disease in Acute T Lymphoblastic Leukemia. Science Translational Medicine, 2012, 4, 134ra63.	12.4	207
36	Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood, 2006, 107, 2639-2642.	1.4	204

#	Article	IF	Citations
37	Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood, 2012, 120, 833-842.	1.4	201
38	Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199. Cancer Discovery, 2014, 4, 1074-1087.	9.4	201
39	Philadelphia chromosomeâ€“like acute lymphoblastic leukemia. Blood, 2017, 130, 2064-2072.	1.4	198
40	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood, 2017, 129, e26-e37.	1.4	195
41	Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood, 2015, 125, 1759-1767.	1.4	189
42	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia: Results of Childrenâ€™s Oncology Group Trial AALL0622. Journal of Clinical Oncology, 2018, 36, 2306-2314.	1.6	185
43	Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2021, 325, 833.	7.4	177
44	Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood, 2013, 121, 898-904.	1.4	174
45	Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. Journal of Clinical Oncology, 2007, 25, 813-819.	1.6	171
46	Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood, 2018, 131, 995-999.	1.4	170
47	ARID5B Genetic Polymorphisms Contribute to Racial Disparities in the Incidence and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2012, 30, 751-757.	1.6	165
48	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Childrenâ€™s Oncology Group AALL0434 Methotrexate Randomization. Journal of Clinical Oncology, 2018, 36, 2926-2934.	1.6	164
49	Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncology, The, 2015, 16, 1659-1666.	10.7	161
50	Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood, 2018, 131, 1350-1359.	1.4	158
51	Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia, 2019, 33, 884-892.	7.2	158
52	Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood, 2013, 121, 485-488.	1.4	156
53	Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11306-11311.	7.1	151
54	Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2013, 60, 957-963.	1.5	149

#	Article	IF	Citations
55	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell, 2018, 33, 937-948.e8.	16.8	142
56	Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. British Journal of Haematology, 2011, 152, 677-687.	2.5	139
57	Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH. Clinical Cancer Research, 2014, 20, 4540-4548.	7.0	138
58	Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood, 2017, 129, 177-187.	1.4	138
59	Childrenâ€™s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2020, 38, 3282-3293.	1.6	136
60	Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature, 2015, 521, 357-361.	27.8	127
61	Intrachromosomal Amplification of Chromosome 21 Is Associated With Inferior Outcomes in Children With Acute Lymphoblastic Leukemia Treated in Contemporary Standard-Risk Children's Oncology Group Studies: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2013, 31, 3397-3402.	1.6	125
62	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. Journal of Clinical Oncology, 2018, 36, 591-599.	1.6	121
63	Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell, 2016, 29, 186-200.	16.8	118
64	Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2020, 38, 1897-1905.	1.6	117
65	Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. Human Molecular Genetics, 2014, 23, 4315-4327.	2.9	114
66	The COVIDâ€19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOPâ€E, SIOPâ€PODC, IPSO, PROS, CCI, and St Jude Global. Pediatric Blood and Cancer, 2020, 67, e28409.	1.5	113
67	T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Childrenâ€™s Oncology Group (COG) Study AALL0434. Blood, 2014, 124, 1-1.	1.4	113
68	Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood, 2017, 130, 397-407.	1.4	112
69	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood, 2015, 125, 680-686.	1.4	110
70	Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia. Cancer Cell, 2015, 27, 409-425.	16.8	109
71	Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Childrenâ€™s Oncology Group Trial AALL0331. Journal of Clinical Oncology, 2020, 38, 602-612.	1.6	107
72	SHP-2 and myeloid malignancies. Current Opinion in Hematology, 2004, 11, 44-50.	2.5	106

#	Article	IF	Citations
73	Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Blood, 2013, 121, 4925-4929.	1.4	104
74	Treatment of Infantile Fibrosarcoma With Chemotherapy and Surgery: Results From the Dana-Farber Cancer Institute and Children's Hospital, Boston. Journal of Pediatric Hematology/Oncology, 2002, 24, 722-726.	0.6	103
75	Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood, 2006, 107, 4508-4513.	1.4	103
76	Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatric Blood and Cancer, 2006, 46, 579-585.	1.5	103
77	A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatric Blood and Cancer, 2015, 62, 1717-1724.	1.5	103
78	Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood, 2011, 118, 2191-2199.	1.4	102
79	Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. Blood, 2013, 121, 1814-1818.	1.4	102
80	Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia. Blood, 2014, 124, 2487-2497.	1.4	98
81	Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): A therapeutic advances in childhood leukemia (TACL) consortium study. Pediatric Blood and Cancer, 2010, 55, 421-429.	1.5	97
82	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Childrenâ€™s Oncology Group. Blood, 2018, 132, 815-824.	1.4	97
83	Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nature Genetics, 2019, 51, 694-704.	21.4	97
84	Absence of Biallelic TCRÎ³ Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2010, 28, 3816-3823.	1.6	93
85	Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol Escherichia coli L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4. Journal of Clinical Oncology, 2014, 32, 3874-3882.	1.6	91
86	Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature, 2018, 553, 511-514.	27.8	90
87	Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2016, 34, 2133-2140.	1.6	88
88	Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia. Cancer Discovery, 2021, 11, 2846-2867.	9.4	83
89	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed Tâ€cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatric Blood and Cancer, 2015, 62, 1176-1183.	1.5	76
90	Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL. Blood Advances, 2017, 1, 1657-1671.	5.2	76

#	Article	IF	Citations
91	Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nature Communications, 2017, 8, 2127.	12.8	75
92	Prenatal origin ofTEL-AML1-positive acute lymphoblastic leukemia in children born in California. Genes Chromosomes and Cancer, 2003, 37, 36-43.	2.8	74
93	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. Nature Communications, 2015, 6, 7553.	12.8	72
94	Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes. JCI Insight, 2018, 3, .	5.0	71
95	Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. Blood, 2015, 125, 516-524.	1.4	69
96	Genetic predispositions to childhood leukemia. Therapeutic Advances in Hematology, 2013, 4, 270-290.	2.5	68
97	Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL. Cancer Discovery, 2019, 9, 436-451.	9.4	67
98	Characterization of leukemias with ETV6-ABL1 fusion. Haematologica, 2016, 101, 1082-1093.	3.5	66
99	Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study <scp>AALL0331</scp>. International Journal of Cancer, 2016, 138, 332-339.	5.1	66
100	Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (â€œPh-likeâ€•or â€œBCR-ABL1-Likeâ€) Signature For Therapeutic Targeting and Clinical Intervention. Blood, 2013, 122, 826-826.	1.4	65
101	Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia Research, 2005, 29, 459-462.	0.8	64
102	Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2017, 35, 2527-2534.	1.6	64
103	TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches. Current Opinion in Hematology, 2002, 9, 345-352.	2.5	61
104	Improving outcomes for highâ€risk ALL: Translating new discoveries into clinical care. Pediatric Blood and Cancer, 2011, 56, 984-993.	1.5	60
105	Childhood acute lymphoblastic leukemia: Integrating genomics into therapy. Cancer, 2015, 121, 3577-3590.	4.1	59
106	Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. Nature Communications, 2019, 10, 5348.	12.8	58
107	Identification of Cryptotanshinone as an Inhibitor of Oncogenic Protein Tyrosine Phosphatase SHP2 (PTPN11). Journal of Medicinal Chemistry, 2013, 56, 7212-7221.	6.4	57
108	Ph-like acute lymphoblastic leukemia. Hematology American Society of Hematology Education Program, 2016, 2016, 561-566.	2.5	57

#	Article	IF	Citations
109	Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. Blood, 2016, 127, 558-564.	1.4	56
110	Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. Journal of Clinical Oncology, 2021, 39, 1437-1447.	1.6	56
111	Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia. Cancer Research, 2019, 79, 2339-2351.	0.9	55
112	A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. Blood, 2009, 113, 1075-1085.	1.4	54
113	Congenital leukemia cutis with subsequent development of leukemia. Journal of the American Academy of Dermatology, 2006, 54, S22-S27.	1.2	51
114	One year followâ€up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatric Blood and Cancer, 2009, 52, 259-262.	1.5	51
115	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331. Blood, 2019, 134, LBA-1-LBA-1.	1.4	51
116	Advances in the Genetics of High-Risk Childhood B-Progenitor Acute Lymphoblastic Leukemia and Juvenile Myelomonocytic Leukemia: Implications for Therapy. Clinical Cancer Research, 2012, 18, 2754-2767.	7.0	50
117	Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia. Molecular Cancer Therapeutics, 2015, 14, 364-374.	4.1	49
118	Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia. Blood, 2017, 129, 3000-3008.	1.4	48
119	Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. Leukemia, 2018, 32, 2126-2137.	7.2	48
120	Phase I trial of the mTOR inhibitor everolimus in combination with multiâ€agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2018, 65, e27062.	1.5	48
121	Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2018, 65, e26873.	1.5	48
122	Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2019, 37, 780-789.	1.6	48
123	Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies. Future Oncology, 2018, 14, 2115-2129.	2.4	47
124	Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very highâ€risk stratum of patients with newly diagnosed highâ€risk Bâ€lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer, 2018, 124, 1150-1159.	4.1	46
125	FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Childrenâ€™s Oncology Group trial AALL0631. Leukemia, 2021, 35, 1279-1290.	7.2	46
126	Dysregulated RasGRP1 Responds to Cytokine Receptor Input in T Cell Leukemogenesis. Science Signaling, 2013, 6, ra21.	3.6	45

#	Article	IF	Citations
127	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. Journal of Clinical Oncology, 2022, 40, 2106-2118.	1.6	45
128	A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology. Nature Communications, 2016, 7, 10635.	12.8	44
129	Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. Blood, 2019, 133, 724-729.	1.4	44
130	Juvenile Myelomonocytic Leukemia: Molecular Pathogenesis Informs Current Approaches to Therapy and Hematopoietic Cell Transplantation. Frontiers in Pediatrics, 2014, 2, 25.	1.9	43
131	Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. Haematologica, 2015, 100, 17-22.	3.5	43
132	Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 629-636.	1.5	43
133	Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells. Leukemia, 2019, 33, 181-190.	7.2	43
134	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Childrenâ€™s Oncology Group AALL0434. Journal of Clinical Oncology, 2020, 38, 3062-3070.	1.6	42
135	A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase. Blood, 2018, 132, 555-555.	1.4	42
136	Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. Journal of Clinical Oncology, 2022, 40, 956-967.	1.6	42
137	Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies. Molecular Cancer Therapeutics, 2013, 12, 1738-1748.	4.1	41
138	Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Childrenâ€™s Oncology Group Study AALL1131. Journal of Clinical Oncology, 2020, 38, 2628-2638.	1.6	41
139	SOS1 mutations are rare in human malignancies: Implications for Noonan syndrome patients. Genes Chromosomes and Cancer, 2008, 47, 253-259.	2.8	40
140	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Childrenâ€™s Oncology Group (COG). Leukemia, 2018, 32, 1370-1379.	7.2	40
141	Advancing <scp>RAS/RASopathy</scp> therapies: An NCIâ€sponsored intramural and extramural collaboration for the study of <scp>RASopathies</scp>. American Journal of Medical Genetics, Part A, 2020, 182, 866-876.	1.2	40
142	Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group. Leukemia, 2021, 35, 3272-3277.	7.2	40
143	Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2017, 35, 2700-2707.	1.6	38
144	Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2. Journal of Medicinal Chemistry, 2019, 62, 1125-1137.	6.4	38

#	Article	IF	Citations
145	Severe pegaspargase hypersensitivity reaction rates (grade â‰¥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on childrenâ€™s oncology group (COG) clinical trials. Leukemia and Lymphoma, 2018, 59, 1624-1633.	1.3	37
146	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2018, 215, 3094-3114.	8.5	37
147	Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. Blood, 2019, 134, 1227-1237.	1.4	37
148	Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia. Blood, 2021, 137, 364-373.	1.4	37
149	A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621. Blood, 2019, 134, 741-741.	1.4	36
150	PI3K p110Î´ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML. Blood, 2014, 123, 2838-2842.	1.4	35
151	Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia. Blood, 2021, 137, 168-177.	1.4	35
152	International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia. Clinical Cancer Research, 2021, 27, 158-168.	7.0	35
153	Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia. JAMA Oncology, 2022, 8, 354.	7.1	35
154	Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. Blood Advances, 2018, 2, 529-533.	5.2	34
155	Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. Blood, 2008, 111, 1124-1127.	1.4	33
156	Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. Cancer Genetics, 2019, 238, 62-68.	0.4	32
157	Mixedâ€phenotype acute leukemia: A cohort and consensus research strategy from the Childrenâ€™s Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. Cancer, 2020, 126, 593-601.	4.1	32
158	Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. Nature Cancer, 2020, 1, 1113-1127.	13.2	32
159	Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. Lancet Haematology,the, 2021, 8, e55-e66.	4.6	32
160	MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. ELife, 2013, 2, e00825.	6.0	32
161	Childhood Myelodysplastic Syndrome: Focus on the Approach to Diagnosis and Treatment of Juvenile Myelomonocytic Leukemia. Hematology American Society of Hematology Education Program, 2010, 2010, 357-362.	2.5	31
162	Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: A report from the children's oncology group. Pediatric Blood and Cancer, 2015, 62, 414-418.	1.5	31

#	Article	IF	Citations
163	Longitudinal analysis of qualityâ€ofâ€life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. Cancer, 2018, 124, 571-579.	4.1	31
164	Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Childrenâ€™s Oncology Group (COG) study.. Journal of Clinical Oncology, 2019, 37, 10008-10008.	1.6	31
165	Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study. Cancer Genetics, 2015, 208, 1-18.	0.4	30
166	MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. Neuro-Oncology, 2022, 24, 1845-1856.	1.2	30
167	Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors. Clinical Cancer Research, 2017, 23, 1852-1861.	7.0	29
168	Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. Nature Genetics, 2022, 54, 170-179.	21.4	29
169	Isolated late testicular relapse of Bâ€cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and responseâ€based testicular radiation: A Children's Oncology Group study. Pediatric Blood and Cancer, 2018, 65, e26928.	1.5	28
170	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Advances, 2021, 5, 504-512.	5.2	28
171	Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood, 2022, 139, 1785-1793.	1.4	28
172	Fusion driven JMML: a novel CCDC88Câ€“FLT3 fusion responsive to sorafenib identified by RNA sequencing. Leukemia, 2020, 34, 662-666.	7.2	27
173	Congenital Fibrosarcoma of the Upper Extremity. Plastic and Reconstructive Surgery, 1998, 102, 1158-1162.	1.4	26
174	Chromosome 12p Deletions inTEL-AML1Childhood Acute Lymphoblastic Leukemia Are Associated with Retrotransposon Elements and Occur Postnatally. Cancer Research, 2008, 68, 9935-9944.	0.9	26
175	Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatric Blood and Cancer, 2018, 65, e27034.	1.5	26
176	Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Childrenâ€™s Oncology Group AALL07P4. Leukemia and Lymphoma, 2019, 60, 1740-1748.	1.3	25
177	Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. Haematologica, 2019, 104, 986-992.	3.5	25
178	Molecular and phenotypic diversity of <I>CBL</I>-mutated juvenile myelomonocytic leukemia. Haematologica, 2022, 107, 178-186.	3.5	25
179	Epigenetic silencing of <scp>SOCS</scp>5 potentiates <scp>JAK</scp>â€<scp>STAT</scp> signaling and progression of Tâ€cell acute lymphoblastic leukemia. Cancer Science, 2019, 110, 1931-1946.	3.9	24
180	Patients with Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia (ALL) Have High Levels of Minimal Residual Disease (MRD) at the End of inductionâ€”A Children's Oncology Group (COG) Study.. Blood, 2009, 114, 9-9.	1.4	24

#	Article	IF	Citations
181	Inhibition of SRC Corrects GM-CSF Hypersensitivity That Underlies Juvenile Myelomonocytic Leukemia. Cancer Research, 2013, 73, 2540-2550.	0.9	23
182	CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+) Tj ETQq0 0 0 rgBT /Overlock 10	1.4	23
183	Molecular characteristics of a pancreatic adenocarcinoma associated with Shwachmanâ€Diamond syndrome. Pediatric Blood and Cancer, 2013, 60, 754-760.	1.5	22
184	Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies. Clinical Cancer Research, 2017, 23, 5329-5338.	7.0	21
185	The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Contextâ€“Dependent Manner in Pediatric Acute Lymphoblastic Leukemia. Molecular Cancer Research, 2020, 18, 1153-1165.	3.4	20
186	RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. Journal of Clinical Investigation, 2021, 131, .	8.2	20
187	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. Journal of Clinical Investigation, 2021, 131, .	8.2	20
188	Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (ZarnestraÂ®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Childrenâ€™s Oncology Group Study.. Blood, 2005, 106, 2587-2587.	1.4	20
189	A New System Identification Approach to Identify Genetic Variants in Sequencing Studies for a Binary Phenotype. Human Heredity, 2014, 78, 104-116.	0.8	19
190	Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. Journal of Clinical Oncology, 2021, 39, 1540-1552.	1.6	19
191	On-Going Evolution Of IGH In B-Cell Precursor Acute Lymphoblastic Leukemia Does Not Substantially Affect Day 29, Post-Treatment MRD Quantification By High-Throughput Sequencing. Blood, 2013, 122, 1341-1341.	1.4	19
192	Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. PLoS ONE, 2019, 14, e0221288.	2.5	16
193	Association ofGATA3Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2021, 113, 408-417.	6.3	16
194	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discovery, 2021, 11, 1424-1439.	9.4	16
195	KRAS insertion mutations are oncogenic and exhibit distinct functional properties. Nature Communications, 2016, 7, 10647.	12.8	15
196	Next Generation Transcriptomic Resequencing Identifies Novel Genetic Alterations in High-Risk (HR) Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) HR ALL TARGET Project.. Blood, 2009, 114, 704-704.	1.4	15
197	Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Childrenâ€™s Oncology Group (COG) Study AALL0331. Blood, 2014, 124, 793-793.	1.4	15
198	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. Blood, 2018, 132, 565-565.	1.4	14

#	Article	IF	Citations
199	Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Childrenâ€™s Oncology Group Study AALL0232. Leukemia, 2022, 36, 648-655.	7.2	14
200	Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia. Pediatric Blood and Cancer, 2019, 66, e27948.	1.5	13
201	Juvenile myelomonocytic leukemia in the molecular era: a clinicianâ€™s guide to diagnosis, risk stratification, and treatment. Blood Advances, 2021, 5, 4783-4793.	5.2	13
202	Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Childrenâ€™s Oncology Group (COG) AALL0331. Blood, 2013, 122, 837-837.	1.4	13
203	Lack of TEL/AML1 fusion in pediatric AML: further evidence for lineage specificity of TEL/AML1. Leukemia Research, 1998, 22, 461-464.	0.8	12
204	Translocation (2;8)(p12;q24) associated with a cryptic t(12;21)(p13;q22) TEL/AML1 gene rearrangement in a child with acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2000, 122, 79-82.	1.0	12
205	Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. Blood, 2014, 123, 1426-1427.	1.4	12
206	Downregulating Notch counteracts KrasG12D-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm. Leukemia, 2019, 33, 671-685.	7.2	12
207	Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study. Blood, 2019, 134, 2649-2649.	1.4	12
208	Robust Detection Of Minimal Residual Disease In Unselected Patients With B-Cell Precursor Acute Lymphoblastic Leukemia By High-Throughput Sequencing Of IGH. Blood, 2013, 122, 2550-2550.	1.4	12
209	Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434. Blood, 2015, 126, 794-794.	1.4	12
210	Sexâ€based disparities in outcome in pediatric acute lymphoblastic leukemia: a Childrenâ€™s Oncology Group report. Cancer, 2022, 128, 1863-1870.	4.1	12
211	Generation of a human Juvenile myelomonocytic leukemia iPSC line, CHOPi001-A, with a mutation in CBL. Stem Cell Research, 2018, 31, 157-160.	0.7	11
212	Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Childrenâ€™s Oncology Group. Haematologica, 2019, 104, e517-e520.	3.5	11
213	Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition. Blood, 2015, 126, 3792-3792.	1.4	11
214	Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Childrenâ€™s Oncology Group AALL0631 trial. Haematologica, 2022, 107, 1205-1208.	3.5	11
215	Mutations in the RAS Signaling, B-Cell Development, TP53/RB1, and JAK Signaling Pathways Are Common in High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project.. Blood, 2009, 114, 85-85.	1.4	10
216	Identification of CRLF2 Genomic Lesions in Patients with Pediatric B-Precursor Acute Lymphoblastic Leukemia (BCP ALL) by Flow Cytometry or Quantitative RT-PCR: A Children's Oncology Group (COG) Stud.. Blood, 2012, 120, 2529-2529.	1.4	10

#	Article	IF	Citations
217	Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731. Blood, 2021, 138, 2304-2304.	1.4	10
218	Molecular Mechanisms of ARID5B-Mediated Genetic Susceptibility to Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2022, 114, 1287-1295.	6.3	10
219	Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL. Biomarker Research, 2018, 6, 27.	6.8	9
220	Genetic characterization and therapeutic targeting of MYCâ€rearranged T cell acute lymphoblastic leukaemia. British Journal of Haematology, 2019, 185, 169-174.	2.5	9
221	Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug Resistance. Cancer Research, 2020, 80, 5189-5202.	0.9	9
222	Genome-Wide Association Study of Susceptibility Loci for TCF3-PBX1 Acute Lymphoblastic Leukemia in Children. Journal of the National Cancer Institute, 2021, 113, 933-937.	6.3	9
223	Prognostic impact of minimal residual disease at the end of consolidation in NCI standardâ€risk Bâ€lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2021, 68, e28929.	1.5	9
224	Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples. Leukemia, 2021, , .	7.2	9
225	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. Pediatric Blood and Cancer, 2019, 66, e27681.	1.5	8
226	Induction Toxicities Are More Frequent in Young Adults Compared to Children Treated on the Children's Oncology Group (COG) First Relapse B-Lymphoblastic Leukemia Clinical Trial AALL1331. Blood, 2018, 132, 1382-1382.	1.4	8
227	Genomic Characterization and Experimental Modeling Of BCR-ABL1-Like Acute Lymphoblastic Leukemia. Blood, 2013, 122, 232-232.	1.4	8
228	Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome. Blood, 2013, 122, 825-825.	1.4	8
229	Treatment-Related Mortality (TRM) in Children with Down Syndrome (DS) and B-Lymphoblastic Leukemia (B-ALL): An Interim Report from the Children's Oncology Group Trials AALL0932 and AALL1131. Blood, 2015, 126, 2502-2502.	1.4	8
230	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331. Blood, 2021, 138, 363-363.	1.4	8
231	Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy. Blood, 2020, 136, 37-38.	1.4	8
232	Sustained remission with azacitidine monotherapy and an aberrant precursor Bâ€lymphoblast population in juvenile myelomonocytic leukemia. Pediatric Blood and Cancer, 2019, 66, e27905.	1.5	7
233	Case report: Impact of<scp>BITE</scp>on<scp>CAR</scp>â€T cell expansion. Advances in Cell and Gene Therapy, 2019, 2, e50.	0.9	7
234	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. Clinical Pharmacology and Therapeutics, 2021, 110, 794-802.	4.7	7

#	Article	IF	Citations
235	Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131. Blood, 2018, 132, 35-35.	1.4	7
236	Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study.. Blood, 2009, 114, 1580-1580.	1.4	7
237	Lack of Somatic Sequence Mutations In Protein Tyrosine Kinase Genes Other Than the JAK Kinase Family In High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project. Blood, 2010, 116, 2752-2752.	1.4	7
238	Adjuvant CD49d Blockade Eradicates Chemoresistant ALL. Blood, 2010, 116, 869-869.	1.4	7
239	Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Children's Oncology Group (COG) Trial AALL0622. Blood, 2012, 120, 137-137.	1.4	7
240	Identification of Novel LNK Mutations In Patients with Chronic Myeloproliferative Neoplasms and Related Disorders. Blood, 2010, 116, 315-315.	1.4	7
241	GermlineRRAS2mutations are not associated with Noonan syndrome. Journal of Medical Genetics, 2016, 53, 728-728.	3.2	6
242	SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome. Blood, 2021, 137, 1835-1838.	1.4	6
243	Aurora A kinase as a target for therapy in <i>TCF3-HLF</i> rearranged acute lymphoblastic leukemia. Haematologica, 2021, 106, 2990-2994.	3.5	6
244	Using genomics to define pediatric blood cancers and inform practice. Hematology American Society of Hematology Education Program, 2018, 2018, 286-300.	2.5	6
245	Acute Lymphoblastic Leukemia with Zinc-Finger Protein 384 (ZNF384)-Related Rearrangements: A Retrospective Analysis from the Ponte Di Legno Childhood ALL Working Group. Blood, 2019, 134, 652-652.	1.4	6
246	High-Throughput Screening by Flow Cytometry Identifies Reduced Expression of CD48 As a Universal Characteristic of T-ALL and a Suitable Target for Minimal Residual Disease (MRD) Detection. Blood, 2011, 118, 2547-2547.	1.4	6
247	Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 618-618.	1.4	6
248	Incidence of Allergic Reactions to Pegaspargase (PEG) Administered Intramuscularly Versus Intravenously (IM vs. IV) in Children and Young Adults with High Risk B-Lymphoblastic Leukemia (HR) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 1303-1303.	1.4	6
249	Amplification of AML1 Does Not Impact Early Outcome of Children with Acute Lymphoblastic Leukemia (ALL) Treated with Risk-Directed Chemotherapy: A Report From the Children's Oncology Group (COG).. Blood, 2009, 114, 2598-2598.	1.4	6
250	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. Blood, 2014, 124, 63-63.	1.4	6
251	JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. Leukemia, 2022, 36, 1499-1507.	7.2	6
252	Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement. Haematologica, 2023, 108, 717-731.	3.5	6

#	Article	IF	Citations
253	Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2022, 114, 1167-1175.	6.3	6
254	Pediatric MDS: GATA screen the germline. Blood, 2016, 127, 1377-1378.	1.4	5
255	High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL. SLAS Discovery, 2018, 23, 732-741.	2.7	5
256	Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. JAMA Oncology, 2021, 7, 1521-1528.	7.1	5
257	Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia. Blood, 2018, 132, 1405-1405.	1.4	5
258	Safety of Palbociclib in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoma: A Children's Oncology Group Pilot Study. Blood, 2020, 136, 20-21.	1.4	5
259	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.. Blood, 2012, 120, 2466-2466.	1.4	5
260	In Vivo Efficacy of PI3K Pathway Signaling Inhibition for Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia. Blood, 2013, 122, 2672-2672.	1.4	5
261	Effect of High-Dose Methotrexate (HD-MTX) Vs Capizzi Methotrexate/Pegaspargase (C-MTX/ASNase) on Osteonecrosis (ON) Incidence in Children and Young Adults with T-Acute Lymphoblastic Leukemia (T-ALL): Results of Childrenâ€™s Oncology Group (COG) Study AALL0434. Blood, 2014, 124, 3649-3649.	1.4	5
262	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). Blood, 2015, 126, 807-807.	1.4	5
263	BCL-2, a Therapeutic Target for High Risk Hypodiploid B-Cell Acute Lymphoblastic Leukemia. Blood, 2016, 128, 280-280.	1.4	5
264	Anti-Pegaspargase, Anti-Calaspargase Pegol , and Anti-Polyethelene Glycol Antibody Incidence in High Risk Acute Lymphoblastic Leukemia Patients Receiving Pegaspargase or Calaspargase Pegol and Associated Anaphylactic or Hypersensitivity Reaction Rates: Results from Children's Oncology Group (COG) Study AALL07P4. Blood, 2016, 128, 3965-3965.	1.4	5
265	Klinefelter syndrome and 47,<scp>XYY</scp> syndrome in children with B cell acute lymphoblastic leukaemia. British Journal of Haematology, 2017, 179, 843-846.	2.5	4
266	Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia. Blood Advances, 2021, 5, 5507-5518.	5.2	4
267	FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study. Blood, 2019, 134, 1293-1293.	1.4	4
268	Factors Influencing Survival after Relapse from Childhood ALL: A Childrenâ€™s Oncology Group Study.. Blood, 2006, 108, 1855-1855.	1.4	4
269	Large Regions of Uniparental Disomy (UPD) Establish Clonal Hematopoietic Stem Cell Selection in a Subset of Myelodysplastic Syndrome (MDS) Patients with Normal Bone Marrow Cell Karyotypes.. Blood, 2007, 110, 120-120.	1.4	4
270	Thymic Stromal Lymphopoietin Stimulation of Pediatric Acute Lymphoblastic Leukemias with CRLF2 Alterations Induces JAK/STAT and PI3K Phosphosignaling. Blood, 2010, 116, 410-410.	1.4	4

#	Article	IF	Citations
271	Comparison Of Mutational Profiles Of Diagnosis and Relapsed Pediatric B-Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. Blood, 2013, 122, 824-824.	1.4	4
272	The Genomic Landscape of Childhood T-Lineage Acute Lymphoblastic Leukemia. Blood, 2015, 126, 691-691.	1.4	4
273	Potent Efficacy of Combined PI3K/mTOR and JAK or SRC/ABL Inhibition in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia. Blood, 2015, 126, 798-798.	1.4	4
274	Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Based on Blast Genotype at Diagnosis: A Report from the Children's Oncology Group. Blood, 2016, 128, 451-451.	1.4	4
275	Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia. Blood, 2016, 128, 454-454.	1.4	4
276	IKZF1 and 22q11.22 Deletions and PDGFRA Gains Are Associated with Poor Outcome in Down Syndrome Acute Lymphoblastic Leukemia. Blood, 2012, 120, 289-289.	1.4	4
277	MEK Inhibition Demonstrates Activity in Relapsed, Refractory Patients with Juvenile Myelomonocytic Leukemia: Results from COG Study ADVL1521. Blood, 2021, 138, 3679-3679.	1.4	4
278	CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia. Blood Advances, 2023, 7, 251-255.	5.2	4
279	High-Throughput Sequencing to Detect Minimal Residual Disease in Acute T Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S369.	0.4	3
280	Characterization of PAX5-driven Subtypes in B-progenitor Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S183.	0.4	3
281	Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. Blood, 2021, 137, 1550-1552.	1.4	3
282	The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment. Haematologica, 2021, 106, 2242-2245.	3.5	3
283	Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma. Blood Advances, 2021, 5, 2890-2900.	5.2	3
284	JMML tumor cells disrupt normal hematopoietic stem cells by imposing inflammatory stress through overproduction of IL-1Î². Blood Advances, 2021, , .	5.2	3
285	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium. Blood, 2018, 132, 261-261.	1.4	3
286	Development of an Allele-Specific Minimal Residual Disease Assay for Patients with Juvenile Myelomonocytic Leukemia-Moving beyond Clinical Assessment.. Blood, 2006, 108, 2681-2681.	1.4	3
287	A Novel Assay for Juvenile Myelomonocytic Leukemia Based on Aberrant Signaling Networks Measured Via Phospho-Specific Flow Cytometry Reduces Diagnosis Time from Weeks to Days.. Blood, 2007, 110, 546-546.	1.4	3
288	Genome-Wide Analysis of Genetic Alterations In Hypodiploid Acute Lymphoblastic Leukemia Identifies a High Frequency of Mutations Targeting the IKAROS Gene Family and Ras Signaling. Blood, 2010, 116, 411-411.	1.4	3

#	Article	IF	Citations
289	Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232. Blood, 2011, 118, 1440-1440.	1.4	3
290	A BCR-ABL1-Like Gene Expression Profile Confers a Poor Prognosis In Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From Children's Oncology Group (COG) AALL0232. Blood, 2011, 118, 743-743.	1.4	3
291	GATA2 Mutations In Pediatric Myelodysplastic Syndromes and Bone Marrow Failure. Blood, 2013, 122, 1520-1520.	1.4	3
292	Functional Analysis of Kinase-Activating Fusions in Ph-like Acute Lymphoblastic Leukemia. Blood, 2014, 124, 786-786.	1.4	3
293	Phase Ib Trial of the mTOR Inhibitor Everolimus Given in Combination with Multiagent Chemotherapy in Relapsed Acute Lymphoblastic Leukemia. Blood, 2015, 126, 3765-3765.	1.4	3
294	Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Childrenâ€™s Oncology Group (COG) AALL0932.. Journal of Clinical Oncology, 2020, 38, 10509-10509.	1.6	3
295	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732. Blood, 2021, 138, 3398-3398.	1.4	3
296	Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study. Blood, 2021, 138, 211-211.	1.4	3
297	JAK2 V617F positive polycythemia Vera in a child with neurofibromatosis type I. Pediatric Blood and Cancer, 2008, 51, 689-691.	1.5	2
298	Reply to I.J. Cohen. Journal of Clinical Oncology, 2017, 35, 3989-3991.	1.6	2
299	Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL). Blood, 2018, 132, 1000-1000.	1.4	2
300	Phamacokinetics (PK) Substudy of Rituximab in a Prospective Clinical Trial for Pediatric Chronic Immune Thrombocytopenic Purpura (cITP).. Blood, 2005, 106, 1243-1243.	1.4	2
301	Germline Mutations in CBL Cause a Predisposition to Juvenile Myelomonocytic Leukemia.. Blood, 2009, 114, 310-310.	1.4	2
302	Potential Role Of RUNX1 In The Pathogenesis Of Juvenile Myelomonocytic Leukemia (JMML). Blood, 2013, 122, 45-45.	1.4	2
303	Mixed Lineage Leukemia Rearrangements (MLL-R) Are Determinants of High Risk Disease in Homeobox A (HOXA)-deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Blood, 2015, 126, 694-694.	1.4	2
304	Residual Disease Monitoring By High Throughput Sequencing Provides Risk Stratification in Childhood B-ALL and Identifies a Novel Subset of Patients Having Poor Outcome. Blood, 2016, 128, 1086-1086.	1.4	2
305	The Genomic Landscape of Childhood and Adult Acute Erythroid Leukemia. Blood, 2016, 128, 39-39.	1.4	2
306	Nelarabine May Be Safely Incorporated Into a Phase III Study for Newly Diagnosed T-Lineage Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. Blood, 2010, 116, 865-865.	1.4	2

#	Article	IF	Citations
307	iAMP21 Is Associated with Inferior Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) on Contemporary Children's Oncology Group (COG) Studies. Blood, 2011, 118, 739-739.	1.4	2
308	Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethinically Diverse Populations. Blood, 2012, 120, 877-877.	1.4	2
309	Germline Genetic Variation in ETV6 and Predisposition to Childhood Acute Lymphoblastic Leukemia. Blood, 2015, 126, 695-695.	1.4	2
310	Efficacy of ALL Therapy for WHO2016-Defined Mixed Phenotype Acute Leukemia: A Report from the Children's Oncology Group. Blood, 2017, 130, 883-883.	1.4	2
311	Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report. Blood, 2020, 136, 39-40.	1.4	2
312	Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Childrenâ€™s Oncology Group (COG). Leukemia, 2017, , .	7.2	1
313	Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia. Blood Advances, 2021, 5, 3587-3591.	5.2	1
314	Cytogenetic Subgroups Drive Risk Stratification and Response to Chemotherapy and Blinatumomab in Children and Young Adults with Relapsed B-ALL: A Children's Oncology Group Study. Blood, 2020, 136, 16-17.	1.4	1
315	PTPN11 Mutational Spectrum in Juvenile Myelomonocytic Leukemia and Noonan Syndrome.. Blood, 2004, 104, 3417-3417.	1.4	1
316	Health-Related Quality of Life (HRQL) in Children with Severe, Chronic Immune Thrombocytopenia (cITP) Treated with Rituximab.. Blood, 2005, 106, 5575-5575.	1.4	1
317	Genome-Wide DNA Methylation Analysis Reveals Biological and Clinical Insights In Relapsed Childhood Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. Blood, 2013, 122, 3736-3736.	1.4	1
318	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 60-60.	1.4	1
319	Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis. Blood, 2014, 124, 367-367.	1.4	1
320	Identifying Drug-Resistant Mutations in Ebf1-Pdgfrb Ph-like Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1423-1423.	1.4	1
321	Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia. Blood, 2015, 126, 693-693.	1.4	1
322	Comprehensive Functional Characterization of Germline ETV6 Variants Associated with Inherited Predisposition to Acute Lymphoblastic Leukemia in Children. Blood, 2016, 128, 1085-1085.	1.4	1
323	PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia. Blood, 2016, 128, 604-604.	1.4	1
324	Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG). Blood, 2016, 128, 758-758.	1.4	1

#	Article	IF	Citations
325	ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Blood, 2010, 116, 8-8.	1.4	1
326	Targeting mTOR and JAK2 in Xenograft Models of CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL). Blood, 2011, 118, 249-249.	1.4	1
327	Genomic- and Transcriptomic Profiling Of Acute Lymphoblastic Leukemia With Dicentric Chromosomes. Blood, 2013, 122, 234-234.	1.4	1
328	Characterization of Leukemias with ETV6-ABL1 Fusion. Blood, 2015, 126, 84-84.	1.4	1
329	Whole Exome Sequencing of Pediatric Acute Lymphoblastic Leukemia Patients Identify Mutations in 11 Pathways: A Report from the Children's Oncology Group. Blood, 2016, 128, 455-455.	1.4	1
330	Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia. Blood, 2018, 132, 4026-4026.	1.4	1
331	RUNX2 Regulates Cell Migration in T-Cell Lineage Acute Lymphoblastic Leukemia. Blood, 2019, 134, 3947-3947.	1.4	1
332	Abstract 5399: The NSD2 p.E1099K mutation is enriched at relapse and confers drug resistance in a cell context dependent manner in pediatric acute lymphoblastic leukemia. , 2020, , .		1
333	Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 3487-3487.	1.4	1
334	CD22 low/Bcl-2 high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia. Blood, 2021, 138, 614-614.	1.4	1
335	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). Blood, 2020, 136, 44-45.	1.4	1
336	Minimal residual disease comparison between Ig/TCR PCR versus NGS assays in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: A report from the COG AALL1631 study.. Journal of Clinical Oncology, 2022, 40, 10023-10023.	1.6	1
337	Dysregulation of the transcription factor runx1 in juvenile myelomonocytic leukemia. Experimental Hematology, 2017, 53, S51.	0.4	0
338	ALL-167: A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Relapsed, Resistant, or Intolerant Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) or Have the T315I Mutation. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S271-S272.	0.4	0
339	Poster: ALL-144: Oncogenic Deregulation of BCL11B in Lineage Ambiguous Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S207.	0.4	0
340	Functional Analysis of Leukemia-Associated PTPN11 Mutations in Primary Hematopoietic Cells.. Blood, 2004, 104, 2423-2423.	1.4	0
341	Cytogenetics of Hispanics and Whites with Childhood Acute Lymphoblastic Leukemia in California.. Blood, 2005, 106, 4536-4536.	1.4	0
342	Early Response to Therapy Is Significantly Associated with Genetic Subtype of Acute Lymphoblastic Leukemia: A Report from the Childrenâ€™s Oncology Group.. Blood, 2007, 110, 758-758.	1.4	0

#	Article	IF	Citations
343	Retrospective Survey of Children Treated for Relapsed Acute Lymphoblastic Leukemia (Complete) Tj ETQq1 1 0.784314 rgBT /Overloc Consortium.. Blood, 2007, 110, 854-854.	1.4	0
344	Bcl11a Causes p21Cip1 Down-Regulation and Transplantable Leukemia in Nf1-Deficient Mice.. Blood, 2007, 110, 2657-2657.	1.4	0
345	A Rare Case of JAK2 V617F Positive Polycythemia Vera in a Child with Neurofibromatosis Type I.. Blood, 2007, 110, 4661-4661.	1.4	0
346	Identification of Novel Cluster Groups in High-Risk Pediatric B-Precursor Acute Lymphoblastic Leukemia (HR-ALL) by Gene Expression Profiling: Correlation with Clinical and Outcome Variables. a Childrenâ€™s Oncology Group (COG) Study.. Blood, 2008, 112, 2256-2256.	1.4	0
347	Quantitative RT-PCR for Expression of a Small Subset of Genes Identifies Novel Prognostic Subgroups in High-Risk Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia (HR-ALL): Clinical Applicability of Gene Expression Microarray Data from Childrenâ€™s Oncology Group Trials.. Blood, 2008, 112, 1514-1514.	1.4	0
348	Early Response Characteristics and Blast Cytogenetic FEatures In 5,377 Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): A Children's Oncology Group (COG) Study. Blood, 2010, 116, 414-414.	1.4	0
349	Overcoming Drug Resistance In Acute Lymphoblastic Leukemia by Inhibition of CBP/Î³-Catenin. Blood, 2010, 116, 3264-3264.	1.4	0
350	Targeting Survivin In Recalcitrant Acute Lymphoblastic Leukemia. Blood, 2010, 116, 3263-3263.	1.4	0
351	Targeting mTOR Signaling Is An Effective Treatment Strategy for IKAROS and JAK Kinase Mutated Acute Lymphoblastic Leukemia. Blood, 2010, 116, 3251-3251.	1.4	0
352	Novel Chromosomal Rearrangements and Sequence Mutations in High-Risk Ph-Like Acute Lymphoblastic Leukemia. Blood, 2011, 118, 67-67.	1.4	0
353	Patient-Derived Induced Pluripotent Stem Cells Recapitulate Hematopoietic Abnormalities of Juvenile Myelomonocytic Leukemia. Blood, 2011, 118, 637-637.	1.4	0
354	Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. Blood, 2011, 118, 68-68.	1.4	0
355	High-Throughput Sequencing of T-Cell Receptor Gene Loci for Minimal Residual Disease Monitoring in T Lymphoblastic Leukemia. Blood, 2011, 118, 2545-2545.	1.4	0
356	Clinical Spectrum of RAS-Associated Autoimmune Leukoproliferative Disorder (RALD): A Distinct Clinical Entity Mimicking Juvenile Myelomonocytioc Leukemia (JMML) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2012, 120, 1033-1033.	1.4	0
357	Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children's Oncology Group Cohort. Blood, 2012, 120, 1440-1440.	1.4	0
358	Genome-Wide Association Study Identifies Germline Polymorphisms Associated with Relapse of Childhood Acute Lymphoblastic Leukemia. Blood, 2012, 120, 878-878.	1.4	0
359	Expression Profiling for MEIS1 and HOXA9/10 Identifies an Increased Incidence of MLL Rearrangements in T-ALL: A Children's Oncology Group Study.. Blood, 2012, 120, 2505-2505.	1.4	0
360	Risk Factors For Acute Pancreatitis In Patients With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 3868-3868.	1.4	0

#	Article	IF	Citations
361	Mutations In GATA2 Are Rare In Juvenile Myelomonocytic Leukemia. Blood, 2013, 122, 1526-1526.	1.4	0
362	Overexpression Of Leukemia Associated CblY371H Mutation In Transgenic Mice Causes Dosage Dependent Embryonic Lethality. Blood, 2013, 122, 2515-2515.	1.4	0
363	Leukemic Blasts With The PNH Phenotype: Correlation With Cytogenetics In ALL. Blood, 2013, 122, 2628-2628.	1.4	0
364	Subclonal Mutations in SETBP1 Predict Relapse in Juvenile Myelomonocytic Leukemia. Blood, 2014, 124, 410-410.	1.4	0
365	Deciphering the Epigenetic Landscape of Relapsed Pediatric Acute Lymphoblastic Leukemia. Blood, 2014, 124, 612-612.	1.4	0
366	BCL6 Enables RAS-Mediated Pre-B Cell Transformation in Childhood Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3570-3570.	1.4	0
367	Cryptic Truncating Rearrangements of the Erythropoietin Receptor in Ph-like Acute Lymphoblastic Leukemia. Blood, 2014, 124, 128-128.	1.4	0
368	Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia. Blood, 2014, 124, 284-284.	1.4	0
369	Biochemical and Functional Analysis of Novel KRAS Insertions in MPN and Other Cancers. Blood, 2014, 124, 2207-2207.	1.4	0
370	CblY371H Transgene Combined with Hematopoietic Deletion of the Endogenous c-Cbl Gene Results in GM-CSF Hypersensitivity and Leukocytosis. Blood, 2015, 126, 3672-3672.	1.4	0
371	Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia. Blood, 2015, 126, 556-556.	1.4	0
372	Targeting JAK Pathway-Mutant Acute Lymphoblastic Leukemia. , 2016, 13, .		0
373	Integrated Genomic Analysis of Down Syndrome Acute Lymphoblastic Leukemia Reveals Recurrent Cancer Gene Alterations and Evidence of Frequent Subclonal Driver Events. Blood, 2016, 128, 4083-4083.	1.4	0
374	New Insights into Deregulated Gene Expression Pathways in MLL- and AF10-Rearranged T-Lineage Acute Lymphoblastic Leukemia. Blood, 2016, 128, 2906-2906.	1.4	0
375	Improved Diagnosis of Intrachromosomal Amplification of Chromosome 21 (iAMP21) By Copy Number Profiling. Blood, 2016, 128, 1733-1733.	1.4	0
376	RUNX1 Is a Candidate Transcriptional Effector in Juvenile Myelomonocytic Leukemia. Blood, 2016, 128, 2699-2699.	1.4	0
377	Measurement of Phosphorylated ERK As a Prognostic and Predictive Marker for MEK Inhibition in Pediatric B-Lymphoblastic Leukemia: A Pilot Study. Blood, 2016, 128, 1739-1739.	1.4	0
378	Kinase-Activating Fusions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia (ALL): a Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium. Blood, 2016, 128, 1729-1729.	1.4	0

#	Article	IF	Citations
379	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion: A Report from Children's Oncology Group (COG) AALL0434. Blood, 2018, 132, 659-659.	1.4	0
380	Identification of New Risk Loci and Regulatory Mechanisms Influencing Genetic Susceptibility to Acute Lymphoblastic Leukaemia. Blood, 2019, 134, 650-650.	1.4	0
381	DNA Methylation As a Biomarker of Outcome in JMML: An International Effort Towards Clinical Implementation. Blood, 2019, 134, 1693-1693.	1.4	0
382	Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli-Derived Asparaginases. Blood, 2019, 134, 2586-2586.	1.4	0
383	Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report. Blood, 2021, 138, 2382-2382.	1.4	0
384	The Impact of Genetic Ancestry on the Biology and Prognosis of Childhood Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3476-3476.	1.4	0
385	A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). Blood, 2020, 136, 47-47.	1.4	0
386	Genetic Alterations Precede DNA Methylation Changes in Juvenile Myelomonocytic Leukemia. Blood, 2020, 136, 19-20.	1.4	0
387	Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report. Blood, 2020, 136, 38-39.	1.4	0
388	Abstract 2002: A genome-wide association study identifies novel sepsis risk loci in children with Down syndrome-associated acute lymphoblastic leukemia: A report from the Childrenâ€™s Oncology Group. Cancer Research, 2022, 82, 2002-2002.	0.9	0
389	Effects of age, obesity, and body surface area on asparaginase-associated toxicities during acute lymphoblastic leukemia induction therapy: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2022, 40, 7000-7000.	1.6	0